- Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts.
Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts.
Leukemia research (2013-05-01)
L H van der Helm, N J G M Veeger, M van Marwijk Kooy, A Beeker, O de Weerdt, M de Groot, C Alhan, M Hoogendoorn, L Laterveer, A A van de Loosdrecht, J Koedam, E Vellenga, G Huls
PMID23628552
摘要
The efficacy of azacitidine has been demonstrated in acute myeloid leukemia (AML) patients with 20-30% bone marrow (BM) blasts, but limited data is available on patients with ≥30% blasts. We analyzed 55 newly diagnosed AML patients, treated with azacitidine. The overall response rate was 42%. Median overall survival (OS) was 12.3 months. We confirmed poor-risk cytogenetics, therapy-related AML, performance score ≥2, and white blood cell count ≥15×10(9)/L as independent adverse predictors for OS. The BM blast percentage, however, had no impact on OS (P=0.55). In conclusion, administration of azacitidine is effective in AML patients with 20-30% and >30% BM blasts.